glp-1 weight loss drug news today october 2025 New Daily Pill Aims to Take on Ozempic Weight-loss drug makers announce pricing

The identification of subgroups that are most likely to benefit from GLP-1RAs could be guided by biomarkers, and cardiac imaging may help determine whether the advantages of GLP-1RAs extend beyond the metabolic or obesity phenotypes

McGuire, found that oral semaglutide reduced major adverse cardiovascular events (MACE) to 3.1 events per 100 person-years, compared to 3.7 events in the placebo group a 14% reduction (HR 0.86) over a median follow-up of 49.5 months

3 What's more, a 6-month weight loss study to compare results in a group taking Calocurb with another group getting a placebo has just been completed in New Zealand

Some studies have concluded that the use of GLP-1RAs demonstrates no association with an increased risk of pancreatic cancer [7, 26, 27]

[46] Enebo, L